EQRx, Inc.

EQRx, Inc. (Nasdaq: EQRX) is a biopharmaceutical company that became publicly traded through a SPAC merger with CMLS Holdings, a blank-check vehicle that completed its IPO in 2021. The de-SPAC transaction closed in December 2022, bringing EQRx into the public markets under a mandate to develop and commercialize innovative medicines at significantly reduced prices, with a pipeline concentrated in oncology and immunology. The company filed the referenced 8-K with the Securities and Exchange Commission on November 9, 2023, reflecting its status as an active post-merger reporting issuer in the healthcare and life sciences sector. For full filing histories, SPAC transaction details, and real-time data on EQRx and thousands of other blank-check vehicles, sign up for complete access at SpacDesk.